Company

Ordering
INQUIRY
  1. Home
  2. Disease Models
  3. Urology Disease Models
  4. Peritoneal Fibrosis Model

Peritoneal Fibrosis Model

Peritoneal fibrosis is the end-stage consequence of progressive changes in the peritoneal membrane, often driven by clinical interventions such as peritoneal dialysis (PD). PD provides an alternative to hemodialysis for patients with end-stage renal disease, but 50-80% of patients develop peritoneal fibrosis within one to two years, highlighting the need for effective anti-fibrotic therapies.

Creative Bioarray offers a validated peritoneal fibrosis animal model to support preclinical evaluation of anti-fibrotic drug candidates. This model recapitulates key pathological and functional features of PD-associated peritoneal fibrosis, providing a reliable platform for assessing tissue remodeling, collagen deposition, and peritoneal membrane function, thereby accelerating drug discovery and mechanistic studies.

Fig.1: Schematic diagram illustrating the pathophysiology of peritoneal fibrosis

Fig.1: Schematic diagram of the pathophysiology of peritoneal fibrosis. (Kang et al., 2024)

Our Peritoneal Fibrosis Model

Animal Species

Rat

Modeling Method

Daily intraperitoneal injection of peritoneal dialysis solution (e.g., lactate-buffered, 4.25% glucose).

Endpoints

  • General health: Body weight, survival rate, clinical observation
  • Serum biochemistry: Creatinine, blood urea nitrogen (BUN)
  • Fibrosis markers: Soluble, insoluble, and total collagen content, and hydroxyproline levels in the peritoneum
  • Histological analysis: H&E and Masson's trichrome staining of peritoneum
  • Functional assessment: Peritoneal equilibration test (PET)
  • Molecular analysis: qPCR or Western blot
  • Customized endpoints

Key Features

  • Clinically Relevant

Mimics long-term dialysis-associated injury.

  • Comprehensive Endpoints

Structural, biochemical, functional, and molecular evaluation.

  • Fully Customizable

Study designs tailored to project goals.

Example Data

Fig.2: Representative photographs of Masson staining of parietal peritoneal membrane.

Fig. 2: Masson staining of parietal peritoneal membrane. (Li et al., 2018)

Quotation and Ordering

Interested in leveraging our Peritoneal Fibrosis Model for anti-fibrotic drug discovery or mechanistic research? Please contact us directly or submit an inquiry to discuss your specific project requirements.

References

  1. Kang, Y., et al. Peritoneal fibrosis: from pathophysiological mechanism to medicine. Frontiers in Physiology, 2024, 15: 1438952.
  2. Sun, C.Y., et al. Prevention and Treatment of Peritoneal Dialysis-Associated Fibrosis with Intraperitoneal Anti-Fibrotic Therapy in Experimental Peritoneal Fibrosis. Pharmaceuticals, 2025, 18(2): 188.
  3. Li, L., et al. Inhibiting core fucosylation attenuates glucose-induced peritoneal fibrosis in rats. Kidney International, 2018, 93(6): 1384-1396.

For research use only. Not for any other purpose.

Disease Models

Online Inquiry